Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday.
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday.
Genetic Technologies Announced New Publication Highlights geneType’s ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company","GTG") is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment.
Highlights:
• GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.
Genetic Technologies Announced Earlier Upcoming Launch Of World’s First Comprehensive Risk Test For Breast & Ovarian Cancer
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the Company will launch a ‘World First' Comprehensive Risk Assessment Test which evaluates a women's risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.
Genetic Technologies Announced Monday A Poster Presentation: Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk ASCOGI
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce a poster presentation by Dr Erika Speath at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend.
Genetic Technologies Announced GeneType Published in PLOS ONE – Development of Polygenic Risk Scores for Cardiovascular Diseases and Type 2 Diabetes
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the g